Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US-2015337038-A1 · Nov 26, 2015 · US
Peptides having NF-κB inhibitory activity, or composition comprising same
US9464112B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9464112-B2 |
| Application number | US-201314422643-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 20, 2013 |
| Priority date | Aug 23, 2012 |
| Publication date | Oct 11, 2016 |
| Grant date | Oct 11, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are small peptide fragments derived from the NF-κB p65 subunit and a pharmaceutical or cosmetic composition comprising the same. The peptides have a NF-κB inhibitory activity, through controlling the transcription-activation of NF-κB. The peptides inhibit the expressions of pro-inflammatory mediators, which are induced by NF-κB, and also inhibit the transmigration of leukocytes, thereby exhibiting an anti-inflammatory activity. Especially, the peptides have excellent inhibitory activities against dermatitis and skin aging. And also, the peptides inhibit base membrane invasion of cancer cells, thereby exhibiting an inhibitory activity against the growth and/or metastasis of cancer cells.
First claim
Opening claim text (preview).
The invention claimed is: 1. A peptide inhibiting NF-κB activity as set forth in SEQ ID NO: 4. 2. A method for improving inflammation or skin aging through inhibiting activity of NF-κB in a subject, comprising administering a cosmetically effective amount of a peptide derived from the NF-κB p65 subunit, the peptide being selected from the group consisting of the peptide of SEQ ID NO: 1 and the peptide of SEQ ID NO: 4. 3. The method according to claim 2 , wherein the inflammation is dermatitis. 4. The method according to claim 3 , wherein the inflammation is ultraviolet radiation-induced dermatitis. 5. The method according to claim 2 , wherein the skin aging is cutaneous photoaging. 6. The method according to claim 5 , wherein the skin aging is ultraviolet radiation-induced cutaneous photoaging. 7. A method for inhibiting activity of NF-κB in a subject, comprising administering a cosmetically effective amount of a peptide derived from the NF-κB p65 subunit, the peptide being selected from the group consisting of the peptide of SEQ ID NO: 1 and the peptide of SEQ ID NO: 4.
Assignees
Inventors
Classifications
the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu · CPC title
the first amino acid being Arg · CPC title
with the first amino acid being acidic · CPC title
and aliphatic · CPC title
Tripeptides · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9464112B2 cover?
- Provided are small peptide fragments derived from the NF-κB p65 subunit and a pharmaceutical or cosmetic composition comprising the same. The peptides have a NF-κB inhibitory activity, through controlling the transcription-activation of NF-κB. The peptides inhibit the expressions of pro-inflammatory mediators, which are induced by NF-κB, and also inhibit the transmigration of leukocytes, thereb…
- Who is the assignee on this patent?
- Knu Industry Cooperation Found
- What technology area does this patent fall under?
- Primary CPC classification A61K38/07. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 11 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).